| |
|
| |
| DETAILS |
|
How cutting-edge AI innovation & global partnerships are reshaping the next era of biopharma
This discussion will deliver decision-useful insights for founders, pharma executives, & investors navigating a potential seismic shift, where AI accelerates discovery timelines & reduces experimental failures.
What we'll explore
The prospect of China approving one of the first fully AI-designed drugs as early as next year - & what this means for U.S. biotech competition, partnerships, & IP strategy
Strategic lessons for pharma on collaborating with Chinese AI-biotech innovators while managing IP, regulatory, & compliance considerations
Where the biggest opportunities are emerging, from early discovery & generative design to clinical acceleration & global out-licensing
Insights from real deals & examples of how emerging players can position themselves for the next wave of growth
What AI-designed drugs really mean in practice - & how close the industry is to meaningful regulatory milestones
Speakers:
Suguna Rachakonda, PhD, MBA, is a Vice President at Insilico Medicine, the AI biotech building a digital Einstein to reinvent drug discovery. Following its $293 million Hong Kong IPO in December, the AI-driven biotech continues expanding its global R&D footprint, including strategic CNS & autoimmune partnerships with China Medical System.
Winston Ma is a partner at Dragon Global, an AI-focused investment firm managing over $1 billion in assets, & a China-focused investor, attorney, & author specializing in the global AI & digital economy. He previously spent a decade as Managing Director & Head of the North America Office at China Investment Corporation (CIC), China's sovereign wealth fund.
Patrick (Pan) Zhang is President & Head of Corporate Development at BioMap, the cutting-edge AI/ML protein design startup backed by Chinese tech giant Baidu & the Hong Kong government. He led the company's strategic partnerships & global collaborations, including a $1B+ collaboration that spanned three continents.
Moderated by:
Gadareth Higgs, PhD, Partner at Advantary Capital Partners & founder at Higgs Insights. Dr. Higgs brings more than 15 years of experience in bioinformatics & healthcare strategy, with prior leadership roles at ConcertAI & McKinsey, where he advised on healthcare acquisitions exceeding $1B.
Who should attend:
Founders in AI/biotech, R&D leaders, corporate strategy & business development executives, investors, & policy strategists seeking a practical, forward-looking view of China's role in AI-driven drug discovery.
|
|
|
|
|
|
|
|
